Siponimod, a sphingosine-1-phosphate modulator, consistently slowed disability in secondary progressive multiple sclerosis (MS), according to a phase 3 trial published in the Lancet.
The study included 1 645 patients with secondary progressive MS and moderate or advanced disability (3.0-6.5 on the Expanded Disability Status Scale; 55% needed help walking) who were randomly assigned (2:1) to receive 2 mg of oral siponimod once daily or to placebo for up to 3 years or until their disability had progressed.
Slomski A. Drug Slows Disability Progression in Multiple Sclerosis. JAMA. 2018;319(20):2069. doi:https://doi.org/10.1001/jama.2018.6256
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: